It was one of the greatest innovations vaccination schedule last winter and the results show that it was a complete success. Immunization against respiratory syncytial virus (RSV) in children under six months of age reduced the risk of hospitalization. 83%, which leads to a decrease in expected income by 75% and almost 10,000 hospitalizations avoided. These are the results published in the scientific journal of the International Society of Influenza and Other Respiratory Viruses and published this Monday by the Ministry of Health.
Spain was, in fact, the first country in the world to use immunization, called nirsevimabin such an extensive manner that it contributed, along with the involvement of health workers and parents who turned out en masse to vaccinate their children, to the success of the operation and “the enormous impact of reducing the burden of vaccinating their children.” disease and the associated health care overload,” as highlighted in the Health statement.
Acceptance was high and coverage more than 90%, following calls from health authorities to provide infants with immunization, which has a good safety and effectiveness profile and has already been shown in trials to reduce hospital admissions by 80%.
Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infections. lower respiratory tractamong younger children, especially those associated with bronchiolitis and pneumonia. In Spain, RSV traditionally causes collapse and tension every winter in hospitals and primary care settings, but this year the burden on health care was lower due to high immunization coverage and the effectiveness of nirsevimab, which is a monoclonal antibody.